
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences has demonstrated strong performance in the transcatheter aortic valve replacement (TAVR) market, with revenue growth of 10.6% year-over-year, exceeding consensus estimates. The company's transcatheter mitral and tricuspid technology (TMTT) segment saw impressive sales growth of 48.3% year-over-year, fueled by the successful adoption of products like Pascal and Evoque. Management has expressed increased confidence in achieving its 2026 sales guidance of 8-10% year-over-year growth, further reinforcing positive sentiment around the company's financial prospects.
Bears say
Edwards Lifesciences's financial outlook appears negative primarily due to underperformance in adjusted operating margin, which came in at 23.7%, falling short of the consensus estimate of 25.9% due to elevated SG&A expenses of $603 million. Furthermore, while TAVR and TMTT sales slightly exceeded expectations, the Surgical Structural Heart sales underperformed, adding to concerns over revenue growth sustainability. Additional risks, including competitive pressures in the TAVR market and potential delays in the TMTT pipeline, could further hinder the company's ability to maintain growth and adversely affect its stock performance.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares